(Reuters) -Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after ...

A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...

Federal regulators are asking Novavax to complete an additional clinical trial on its Covid-19 vaccine after previously ...

The U.S. FDA is asking Novavax (NASDAQ:NVAX) to conduct an additional randomized, controlled study of its COVID-19 vaccine ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Let us have a closer look at the formula and the truth behind these claims in this Flush Factor Plus review. This review ...

Developments in genomics are enabling the rise of personalised medicine, with therapies tailored specifically for individuals ...

In part 1, experts explores how assessing individual risk factors is crucial in selecting the appropriate JAK inhibitor for ...

Prime Medicine’s modular editing tech may lower off-target risk, but key data and funding milestones remain ahead. Find out ...

Investing.com -- S&P Global Ratings has downgraded the long-term issuer and issue credit ratings of Sartorius AG (ETR: SATG) from ’BBB’ to ’BBB-’ due to macroeconomic volatility and uncertainty ...

PrimeBiome is supported by a no-risk, 60-day money-back policy. This means customers have the freedom to try the product and ...